Reported Earlier, Alnylam's Vutrisiran Data Highlights Early Impact on Key Cardiac Biomarkers, Alnylam Eyes First-Line Therapy for ATTR Amyloidosis
Reported Earlier, Alnylam's Vutrisiran Data Highlights Early Impact on Key Cardiac Biomarkers, Alnylam Eyes First-Line Therapy for ATTR Amyloidosis
根據早前報道,Alnylam的Vutrisiran數據突出顯示對關鍵心臟生物標誌物的早期影響,Alnylam將首選用於ATTR澱粉樣蛋白沉積症的一線治療。
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that two new data sets from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), were presented in the Late Breaking Clinical Research Session 1 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, which was held virtually. An open access recording of Alnylam presentations will be available on the HFSA website following the session.
領先的核糖核酸治療公司Alnylam Pharmicals, Inc.(納斯達克股票代碼:ALNY)今天宣佈,在美國心力衰竭學會的 Late Breaking 臨床研究第 1 期會議上,Vutrisiran 是正在開發的用於治療 ATTR 澱粉樣變性伴心肌病(ATTR-CM)的研究性 RNAi 治療藥物 Vutrisiran 的 Helios-B 3 期研究的兩個新數據集(HFSA)2024年年度科學會議,該會議以虛擬方式舉行。會議結束後,將在HFSA網站上提供Alnylam演講的開放獲取錄像。
Progression in ATTR-CM is associated with cardiac wall thickening, deterioration in systolic and diastolic function and increases...
Attr-cm 的進展與心壁增厚、收...
登入免費觀看全文
登入/註冊